Bulk Pharmaceutical API Sources for ARYMO ER

Bulk Pharmaceutical API Sources for ARYMO ER

Vendor	Vendor Homepage	Vendor Sku	API Url
Sigma-Aldrich		M9524_SIAL
BenchChem		B1236521
CymitQuimica		CQ_64-31-3
RR Scientific		R4090453
RR Scientific		R6225553

ARYMO ER Bulk API Sources

Last updated: February 19, 2026

This report identifies the current landscape of bulk Active Pharmaceutical Ingredient (API) suppliers for ARYMO ER (extended-release). ARYMO ER is a prescription medication containing extended-release oxycodone hydrochloride. The analysis focuses on identifying potential manufacturers and their regulatory standing, crucial for supply chain security and cost management in drug product manufacturing.

Who Manufactures ARYMO ER Bulk API?

The primary manufacturer identified for the bulk API of ARYMO ER is Mallinckrodt Pharmaceuticals [1]. Mallinckrodt is an integrated pharmaceutical company with a significant presence in opioid manufacturing.

• Mallinckrodt Pharmaceuticals:
  • API Name: Oxycodone Hydrochloride Extended Release
  • Primary Role: Manufacturer and supplier of the bulk API for ARYMO ER.
  • Regulatory Status: Mallinckrodt operates under stringent FDA regulations. Their manufacturing facilities are subject to inspection, and their APIs must meet established pharmacopeial standards. Specific details on facility registrations and past inspection reports are publicly available through FDA databases.
  • History with Opioids: Mallinckrodt has been a long-standing producer of opioid APIs and finished products, including oxycodone. This historical context is relevant to understanding supply chain reliability and potential regulatory scrutiny.

Beyond the direct manufacturer of the ARYMO ER formulation, understanding the broader landscape of oxycodone HCl API production is critical. While Mallinckrodt is the originator and likely primary source for their branded product, the availability of generic oxycodone HCl API from other manufacturers can influence market dynamics and provide alternative sourcing options, especially for generic manufacturers or contract manufacturers.

• Other Oxycodone HCl API Manufacturers (Potential Alternative Sources for Generic Formulations):
  • Amneal Pharmaceuticals: A significant player in the generic API market, Amneal has manufacturing capabilities for controlled substances, including oxycodone HCl [2].
  • Mallinckrodt Pharmaceuticals: As mentioned, Mallinckrodt also supplies generic oxycodone HCl API, often distinct from their branded API supply.
  • Actavis PLC (now part of Teva Pharmaceutical Industries): Actavis was a historical producer of oxycodone API. Teva, its successor, maintains extensive API manufacturing operations.
  • Sun Pharma: A global pharmaceutical company with a broad API portfolio, Sun Pharma is a potential producer of controlled substance APIs.
  • Lannett Company: Known for its generic prescription products, Lannett has manufacturing facilities capable of producing controlled substances.
  • Perrigo Company: While primarily known for over-the-counter products, Perrigo also has a generic pharmaceutical division that may engage in API manufacturing or sourcing.

It is important to note that while these companies produce oxycodone HCl API, their specific involvement in supplying API for ARYMO ER (the branded extended-release formulation) is not publicly confirmed for all entities. Their API is more commonly associated with generic oxycodone products. However, for companies looking to develop or manufacture generic extended-release oxycodone formulations, these are the key players in the bulk API market.

What is the Regulatory Landscape for Oxycodone HCl API Production?

The production and distribution of oxycodone HCl API are highly regulated due to its classification as a Schedule II controlled substance under the U.S. Controlled Substances Act (CSA) [3]. Manufacturers must adhere to strict regulations enforced by the Drug Enforcement Administration (DEA) and the Food and Drug Administration (FDA).

• DEA Registration and Quotas:

  • All manufacturers, distributors, and researchers handling Schedule II substances must obtain a DEA registration [4].
  • The DEA establishes annual aggregate production quotas (APQs) for controlled substances, limiting the total amount that can be manufactured domestically. These quotas directly impact the availability of oxycodone HCl API [5]. Manufacturers must apply for individual quotas within these APQs.
  • Strict record-keeping and reporting requirements are mandated for all transactions involving controlled substances.

• FDA Oversight:

  • Current Good Manufacturing Practices (cGMP): API manufacturers must comply with cGMP regulations outlined in 21 CFR Parts 210 and 211 [6]. This ensures product quality, safety, and efficacy.
  • Drug Master Files (DMFs): API manufacturers typically file Type II DMFs with the FDA. These confidential documents contain detailed information about the API’s manufacturing process, facilities, controls, and specifications. Drug product manufacturers can reference these DMFs in their Abbreviated New Drug Applications (ANDAs) or New Drug Applications (NDAs) [7].
  • Inspections: FDA conducts routine inspections of API manufacturing facilities to ensure compliance with cGMP and other regulations. The inspection history and any enforcement actions against a facility are critical due diligence points.

• International Regulations:

  • For APIs sourced internationally, manufacturers must also comply with the regulations of their respective countries and any import/export requirements stipulated by the DEA and equivalent international bodies.
  • The International Narcotics Control Board (INCB) monitors compliance with international drug control treaties, impacting global supply chains for controlled substances [8].

What are the Key Specifications for ARYMO ER Bulk API?

The specifications for ARYMO ER bulk API are dictated by the regulatory filings for the finished drug product and are based on pharmacopeial standards. While exact proprietary specifications are not public, general requirements for extended-release oxycodone HCl API include:

• Chemical Purity: The API must meet a high degree of chemical purity, typically above 98% or 99%, with strict limits on impurities, including related substances, residual solvents, and heavy metals [9].
• Identification: The API must be unequivocally identified as oxycodone hydrochloride using validated analytical methods (e.g., IR spectroscopy, HPLC).
• Assay: The API must contain a specified amount of oxycodone hydrochloride, usually within a narrow range (e.g., 98.0% to 102.0% on an anhydrous basis).
• Physical Properties: Characteristics like particle size distribution, crystal form (polymorphism), and bulk density are critical for the downstream formulation process, especially for extended-release dosage forms. These properties influence dissolution rates and manufacturing consistency.
• Dissolution Profile (for Extended-Release API): While the primary dissolution testing occurs on the finished dosage form, the inherent characteristics of the API, influenced by its manufacturing process and physical form, contribute to its extended-release properties. Specifications may indirectly address attributes that control release.
• Water Content: The moisture content must be controlled within a specified limit to ensure stability.
• Residual Solvents: Limits for residual solvents used in the manufacturing process are defined by ICH guidelines (e.g., ICH Q3C) and must be met [10].
• Microbial Limits: The API must comply with microbial contamination limits.

The ARYMO ER formulation utilizes specific technologies to achieve its extended-release profile. The API itself may be processed or chosen for characteristics that facilitate this release mechanism, potentially involving specific coatings, particle engineering, or incorporation into polymer matrices during API production or drug product manufacturing.

What are the Supply Chain Risks for ARYMO ER Bulk API?

The supply chain for ARYMO ER bulk API, like other opioid APIs, is subject to significant risks stemming from regulatory, manufacturing, and geopolitical factors.

• Regulatory Scrutiny and Enforcement:

  • Increased DEA Quota Restrictions: The DEA can reduce annual production quotas based on national needs and diversion concerns, directly limiting API availability. Historical data shows fluctuations in oxycodone quotas [5].
  • Manufacturing Facility Audits and Shutdowns: FDA or DEA actions against a manufacturing facility, including inspection failures or cGMP violations, can halt production and disrupt supply.
  • Diversion and Illicit Trade: The inherent risk of diversion of opioid APIs and finished products to the illicit market leads to heightened security requirements and regulatory oversight, increasing compliance costs and potential for supply chain disruptions.

• Manufacturing Dependencies:

  • Single Source Vulnerability: If a critical intermediate or raw material for oxycodone HCl API synthesis is sourced from a limited number of suppliers, disruptions at that point can impact overall API production. Mallinckrodt's historical role as a primary supplier for ARYMO ER creates a significant dependency.
  • Quality Control Failures: Batch failures due to quality control issues can lead to product recalls and significant delays in API release.
  • Labor and Operational Issues: Strikes, natural disasters, or other operational disruptions at manufacturing sites can impede production.

• Geopolitical and Market Factors:

  • International Sourcing Risks: Reliance on international suppliers for raw materials or intermediates exposes the supply chain to geopolitical instability, trade disputes, or changes in foreign regulatory policies.
  • Market Demand Fluctuations: Unforeseen surges in demand for opioid analgesics, coupled with strict supply controls, can create shortages.
  • Litigation and Public Perception: Companies involved in opioid manufacturing face ongoing litigation and negative public perception, which can impact their operational stability and strategic decisions, potentially affecting their commitment to specific product lines or API supply. Mallinckrodt has been involved in significant litigation related to its opioid products [1].

What are the Commercial Implications of API Sourcing for ARYMO ER?

The sourcing of bulk API for ARYMO ER carries substantial commercial implications for its manufacturer, AbbVie (which acquired Allergan, the former marketer of ARYMO ER), and any potential generic competitors.

• Cost of Goods Sold (COGS):

  • API Price Volatility: The price of oxycodone HCl API is influenced by DEA quotas, raw material costs, manufacturing complexity, and regulatory compliance overhead. These factors can lead to significant price fluctuations, impacting COGS.
  • Supplier Negotiation Power: The limited number of primary manufacturers for controlled substance APIs can shift negotiation power towards suppliers, potentially increasing API acquisition costs.
  • Supply Chain Security Investments: Implementing robust security measures, robust quality control systems, and redundant sourcing strategies to mitigate risks adds to the overall cost of API procurement.

• Market Competition (Generic ARYMO ER):

  • ANDA Filings: The availability of a strong patent portfolio for ARYMO ER dictates the timeline for generic entry. Once patents expire, generic manufacturers can file ANDAs for extended-release oxycodone products.
  • API Accessibility for Generics: Generic manufacturers require reliable and cost-effective access to oxycodone HCl API. Their ability to secure sufficient API quantities under DEA quotas is a critical factor in their market entry strategy.
  • Formulation Development: Developing a bioequivalent extended-release generic requires not only the API but also specialized formulation expertise and manufacturing capabilities that can replicate the extended-release profile.

• Intellectual Property (IP) Landscape:

  • Patent Expiry: The patent status of ARYMO ER and its manufacturing processes is paramount. Generic manufacturers will target products with expiring patents.
  • Process Patents: Manufacturers may hold patents on specific API synthesis routes or extended-release technologies, which could block generic competitors or necessitate licensing agreements.
  • Litigation Risk: Patent disputes between branded and generic manufacturers are common and can delay market entry, impacting revenue streams.

• Supply Chain Resilience and Strategy:

  • Dual Sourcing: For critical APIs, establishing relationships with multiple qualified suppliers, even if one is primary, can de-risk the supply chain. This is challenging with DEA-controlled substances due to quota limitations.
  • Vertical Integration: Manufacturers that produce their own API (like Mallinckrodt historically) have greater control over supply and cost, but also bear the full burden of manufacturing and regulatory compliance.
  • Strategic Partnerships: Collaborations with API manufacturers can ensure future supply and influence API specifications to meet product development needs.

The commercial success of ARYMO ER, and the competitive landscape it operates within, is intrinsically linked to the secure, compliant, and cost-effective sourcing of its bulk oxycodone HCl API.

Key Takeaways

• Mallinckrodt Pharmaceuticals is the primary identified manufacturer of bulk Active Pharmaceutical Ingredient (API) for ARYMO ER.
• The production of oxycodone hydrochloride API is strictly regulated by the DEA and FDA, requiring registrations, adherence to quotas, and cGMP compliance.
• Key API specifications include high chemical purity, specific assay ranges, controlled physical properties relevant to extended-release formulation, and stringent limits on impurities and residual solvents.
• Supply chain risks are significant, including regulatory enforcement, DEA quota limitations, manufacturing dependencies, and potential diversion.
• Commercial implications involve the cost of goods sold, market competition from generics, intellectual property considerations, and the need for robust supply chain resilience.

Frequently Asked Questions

1. Can generic manufacturers of extended-release oxycodone directly source API from Mallinckrodt for ARYMO ER equivalents? While Mallinckrodt manufactures oxycodone HCl API, their API for ARYMO ER may be specific to their branded product. Generic manufacturers typically source API from companies that specialize in supplying generic-grade controlled substance APIs, which may or may not include Mallinckrodt's generic offerings. Rigorous qualification of any API supplier is necessary.
2. What are the primary hurdles for new API manufacturers looking to enter the oxycodone HCl market? New entrants face significant hurdles including obtaining DEA registration, securing an allocation within restrictive DEA production quotas, demonstrating cGMP compliance to the FDA through rigorous inspections, establishing robust security protocols for controlled substances, and developing cost-competitive manufacturing processes.
3. How do DEA production quotas impact the availability and cost of ARYMO ER bulk API? DEA production quotas directly limit the total amount of oxycodone HCl API that can be manufactured domestically. When demand exceeds these limits or quotas are reduced, it constrains supply, which can drive up API costs and potentially lead to shortages for both branded and generic drug products.
4. What is the role of Drug Master Files (DMFs) in sourcing ARYMO ER bulk API? API manufacturers submit Type II Drug Master Files (DMFs) to the FDA, detailing their manufacturing process and quality controls. Drug product manufacturers (like the marketer of ARYMO ER or generic equivalents) reference these DMFs in their regulatory applications, allowing the FDA to review the API information without disclosing proprietary details to the drug product applicant. This is a critical step in API supplier qualification.
5. Are there international suppliers for oxycodone HCl API that could serve as alternatives to U.S.-based manufacturers? While international sourcing is possible for many APIs, the production of Schedule II controlled substances like oxycodone HCl is subject to stringent international treaties and national regulations. Obtaining necessary import permits, DEA approval, and ensuring compliance with both U.S. and foreign cGMP standards and controlled substance regulations can be complex and may limit viable international alternatives for U.S. drug product manufacturers.

Citations

[1] Mallinckrodt Pharmaceuticals. (n.d.). Products. Retrieved from https://www.mallinckrodt.com/products (Note: Specific product links for ARYMO ER API are proprietary, general product information cited).

[2] Amneal Pharmaceuticals. (n.d.). API Products. Retrieved from https://www.amneal.com/api-products (Note: Specific product listings for controlled substances may require login or direct inquiry).

[3] Drug Enforcement Administration. (n.d.). Controlled Substances Act. Retrieved from https://www.dea.gov/controlled-substances-act

[4] Drug Enforcement Administration. (n.d.). Registrations. Retrieved from https://www.dea.gov/registrations

[5] Drug Enforcement Administration. (n.d.). Quotas. Retrieved from https://www.dea.gov/quotas (Note: Specific historical quota data is often published annually or upon request).

[6] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (CGMP) Regulations. Retrieved from https://www.fda.gov/drugs/guidance-compliance-regulatory-information/current-good-manufacturing-practice-cgmp-regulations

[7] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from https://www.fda.gov/drugs/drug-master-files

[8] International Narcotics Control Board. (n.d.). Role and Functions. Retrieved from https://www.incb.org/incb/en/role-and-functions.html

[9] United States Pharmacopeia. (n.d.). General Chapters. Retrieved from https://www.uspnf.com/ (Note: Specific monograph requirements for Oxycodone Hydrochloride are found within USP NF).

[10] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Harmonised Tripartite Guideline - Impurities: Guideline for Residual Solvents Q3C(R6). Retrieved from https://www.ich.org/